Previous 10 | Next 10 |
Gainers: [[AKBA]] +8%. [[FATE]] +5%. [[CHMA]] +3.5%. [[UAVS]] +3%. [[ZAGG]] +2%.Losers: [[KLIC]] -5.1%. [[ACRS]] -4.6%. [[LITB]] -2.9%. [[CORR]] -2.6%. [[DPW]] -1.3%. For further details see: CORR, FATE, AKBA and DPW among after-hours movers
Gainers: Precigen (PGEN) +26%. Medigus (MDGS) +24%. Aclaris Therapeutics (ACRS) +17%. cbdMD (YCBD) +15%. Abeona Therapeutics (ABEO) +12%.Losers: Mallinckrodt (MNK) -18%. GeoVax Labs (GOVX) -13%. AgeX Therapeutics (AGE) -12%. COMPASS Pathways (CMPS) -9%. ThermoGen...
Will These High Volume Penny Stocks Make Higher Highs This Month? One of the quickest ways to find penny stocks is by looking at technical trends. As I’ve said in the past, sometimes volume and price will dictate momentum before fundamentals. While that type of action could stem from...
Aclaris Therapeutics (NASDAQ: ACRS ) : Q2 GAAP EPS of -$0.28 beats by $0.07 . More news on: Aclaris Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
WAYNE, Pa., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2020 and provide...
Gainers: Immuron (NASDAQ: IMRN ) +121% . More news on: Immuron Limited, DPW Holdings, Inc., iBio, Inc., Stocks on the move, , Read more ...
Aclaris Therapeutics has submitted an Investigational New Drug application to the FDA for ATI-1777, a topical "soft" Janus kinase 1/3 inhibitor, for moderate to severe atopic dermatitis (AD). More news on: Aclaris Therapeutics, Inc., Healthcare stocks news, Read more ...
WAYNE, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-inflammatory diseases, today announced that it has submitted an Investigational New Drug (IND) Applic...
Carver Bancorp (NASDAQ: CARV ) +232% . More news on: Carver Bancorp, Inc., Urban One, Inc., Energous Corporation, Stocks on the move, , Read more ...
Thinly traded nano cap Aclaris Therapeutics (NASDAQ: ACRS ) rockets 83% premarket on robust volume in reaction to its announcement that the FDA has signed off an an investigator-initiated Phase 2a study evaluating lead candidate ATI-450 (on top of standard-of-care treatment) ...
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company ...
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will part...
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...